Lean tissue often decreases during major weight loss with GLP-1–based medications. But “lean mass lost” and “muscle wasted” are not the same finding.
Imagine someone loses 40 pounds while taking a GLP-1–based weight-loss medication.
Most of that loss is fat. But a body-composition scan shows something else fell too: lean mass.
That number can sound alarming. Was all of it muscle? Did the medication cause the loss? And does less lean mass mean the person is now weaker?
Those questions matter as medications such as semaglutide—and incretin-based treatments such as tirzepatide—produce substantial weight loss for many people. The more weight lost, the more important it becomes to ask what that weight consisted of.
The evidence confirms one thing clearly: absolute lean mass commonly declines during GLP-1–associated weight loss.
But that does not automatically mean these medications are causing abnormal muscle wasting.
Most of the weight lost in major trials is fat. Lean mass is not the same measurement as skeletal muscle. Lean tissue also commonly decreases during substantial weight loss achieved without these medications. And researchers know far more about changes on body-composition scans than they do about changes in actual strength and physical performance.
So the important question is not whether every pound lost comes from fat. It usually does not.
It is whether GLP-1–associated weight loss causes an unusually large or harmful loss of muscle—and whether physical function suffers as a result.
Most of the Weight Lost Is Fat—but Lean Mass Falls Too
Body-composition studies make the basic pattern easy to see.
In a DXA substudy of the SURMOUNT-1 tirzepatide trial, participants taking tirzepatide lost an average of 21.3% of their body weight over 72 weeks. Fat mass fell by 33.9%, while lean mass fell by 10.9%. Roughly three-quarters of the weight lost was fat and one-quarter was lean mass.
That 75/25 split is useful context, not a universal rule. The proportion varies among medications, study populations, amounts of weight loss, and measurement methods.
A 2026 meta-analysis of 20 randomized trials involving nearly 15,800 adults found that lean mass accounted for about 25% to 39% of the weight lost with the incretin-based medications studied. The exact estimate differed among semaglutide, tirzepatide, and liraglutide.
So yes: lean tissue loss is real.
But something else happens at the same time. Because fat generally falls more sharply, a person’s overall body composition can improve even while the absolute number of pounds classified as lean mass goes down.
That apparent contradiction becomes easier to understand once we stop using lean mass and muscle as though they were interchangeable.
A DXA Scan Is Not Measuring “Pounds of Muscle”
This may be the most important distinction in the entire debate.
Many GLP-1 body-composition studies use dual-energy X-ray absorptiometry, or DXA. It is useful for estimating broad body compartments, including fat, bone mineral, and lean soft tissue.
But DXA does not directly measure skeletal muscle.
Skeletal muscle is only one component of the nonfat tissue represented in lean measurements. Body water and other tissues contribute too. International experts on body-composition terminology specifically caution against treating DXA-derived lean measurements as though they were direct measurements of skeletal muscle.
That matters during weight loss because changes in a DXA lean-mass estimate do not necessarily correspond pound-for-pound with actual muscle tissue disappearing.
Muscle can certainly be lost. The measurement simply cannot tell us that every pound of lean-mass decline was skeletal muscle.
And even a direct measurement of muscle size would leave another question unanswered:
What can the muscle still do?
Muscle quantity, strength, and physical function are related. They are not the same outcome.
A scan can therefore identify something worth monitoring without telling us whether clinically important muscle deterioration has occurred.
Weight Loss Itself Changes Lean Tissue
There is another problem with saying a medication “caused muscle loss.”
Substantial weight loss achieved through calorie restriction also tends to reduce fat-free or lean tissue. A smaller body does not lose weight exclusively from stored fat.
That means the fair comparison is not:
GLP-1 treatment versus staying at the same weight.
It is:
GLP-1–associated weight loss versus substantial weight loss achieved another way.
The 2026 meta-analysis made that comparison directly. Lean mass represented about 35% of weight lost in the semaglutide trials, about 25% with tirzepatide, about 27% with liraglutide, and about 26% with intensive lifestyle interventions. Overall, the proportional lean-mass loss did not differ significantly between incretin-based treatment and lifestyle intervention.
Those percentages should not be treated as fixed personal predictions—or as clean head-to-head rankings among drugs. The underlying trials differed considerably.
But the comparison changes the interpretation.
A decline in lean mass during GLP-1 treatment is not, by itself, evidence that the medication is uniquely destroying muscle.
Some lean-tissue loss is part of substantial weight reduction more generally.
That still leaves the question people actually care about: does the person become weaker?
The Evidence on Strength Is Much Thinner
Imagine two people whose scans show similar declines in lean mass.
One now struggles to rise from a chair or carry groceries.
The other is lighter, remains strong, and finds walking and stairs easier than before.
Those are very different outcomes.
Unfortunately, major GLP-1 weight-loss trials have measured body weight and body composition much more extensively than they have directly measured muscle strength, power, or everyday physical performance.
There is some reassuring evidence. Across the STEP trials, people treated with semaglutide generally reported improvements in physical functioning compared with placebo. In STEP 1, for example, 39.8% of participants receiving semaglutide achieved a clinically meaningful improvement on the SF-36 physical-functioning measure, compared with 24.1% receiving placebo.
That makes the simplest “weight loss equals physical decline” story difficult to support.
But these were patient-reported measures of function, not direct tests proving that muscle strength was fully preserved.
And becoming lighter can itself make certain movements easier. Walking, climbing stairs, and rising from a chair all require moving body mass. Someone may lose some lean tissue yet experience better mobility because the total mechanical load they are carrying has fallen substantially.
That is why body composition alone cannot tell us whether the change was harmful.
For the question of muscle health, researchers ultimately need to know more about strength, power, mobility, muscle quality, and everyday function.
Those outcomes are especially important for people who begin treatment with less reserve—such as some older or frail adults—because the same absolute loss may have different consequences depending on where a person started.
The current evidence does not justify assuming serious functional harm is routine.
It also does not justify ignoring muscle preservation.
Preserving Muscle Still Matters During Major Weight Loss
Rejecting the claim that “GLP-1s melt muscle” does not mean lean-tissue loss is irrelevant.
When someone is losing a substantial amount of weight, a reasonable goal is to lose fat while preserving as much useful muscle and physical capacity as possible.
The strongest evidence for doing that still comes mostly from weight-loss research in general rather than trials designed specifically around modern GLP-1 medications.
Resistance exercise has particularly strong support.
A 2025 systematic review and meta-analysis found that adding resistance exercise to dietary weight loss did not substantially change total weight loss, but it reduced fat-free-mass loss, increased fat loss, and produced greater gains in muscular strength than dieting alone.
A newer meta-analysis comparing incretin treatment with lifestyle approaches similarly found the most favorable lean-mass preservation in lifestyle interventions that incorporated resistance training.
Protein intake may also matter. A 2024 meta-analysis of 47 studies in adults with overweight or obesity found that higher protein intake during weight-loss interventions helped preserve muscle mass, although it did not clearly preserve strength or physical function.
That evidence should not be turned into a universal GLP-1 “muscle protection protocol.” Direct trials testing specific exercise and nutrition strategies alongside these medications remain more limited, and individual nutritional or exercise needs can differ.
The broader point is simpler:
Muscle preservation deserves attention during substantial weight loss, regardless of how that weight loss is achieved.
If someone notices declining strength, unusually low food intake, difficulty performing normal activities, or concerns about frailty while undergoing medically supervised weight loss, those issues deserve discussion with the healthcare team managing treatment—not interpretation from a body-composition number alone.
Lean Mass Loss Is Real. “Muscle Wasting” Is a Bigger Claim.
Return to the person who lost 40 pounds.
A scan may genuinely show that some of that weight came from lean tissue.
That matters.
But the scan does not tell us that every lost pound of lean tissue was skeletal muscle. It does not establish that the medication caused disproportionate muscle destruction. And it does not tell us, by itself, whether the person became weaker.
The evidence currently supports a more careful picture:
Most GLP-1–associated weight loss comes from fat.
Absolute lean mass commonly decreases too.
Similar lean-tissue loss occurs during substantial weight loss achieved through other methods.
And the evidence on actual muscle strength and long-term physical function remains less complete than the evidence on body composition.
So the goal should not be to demand that 100% of weight loss come from fat. That is not a realistic standard.
The more useful goal is to lose weight while protecting the strength and physical capacity that matter in everyday life.
Lean mass going down is worth paying attention to. It is not, by itself, proof that GLP-1 medications are causing harmful muscle wasting.
